Véronique Joly1, Charles Burdet2, Roland Landman3, Marie Vigan2, Charlotte Charpentier4, Christine Katlama5, André Cabié6, Aida Benalycherif3, Gilles Peytavin7, Patrick Yeni1, France Mentre2, Anne-Laure Argoud8, Imane Amri8, Diane Descamps4, Yazdan Yazdanpanah1. 1. IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, SMIT, Hôpital Bichat, AP-HP, Paris, France. 2. IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Département d'épidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat, AP-HP, Paris, France. 3. IMEA, Fondation Léon M'BA, Paris, France. 4. IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France. 5. SMIT, Hôpital La Pitié Salpétrière, Paris, France. 6. CIC1424 INSERM, Université des Antilles, SMIT, CHU de Martinique, Fort de France, France. 7. IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Pharmacologie-Toxicologie, Hôpital Bichat, AP-HP, Paris, France. 8. French Agency for Research on AIDS and Viral Hepatitis, Paris, France.
Abstract
OBJECTIVES: To evaluate the dolutegravir+lamivudine combination in virologically suppressed patients living with HIV. METHODS: The ANRS 167 LAMIDOL trial was an open-label, single arm, multicentre trial assessing once-daily dolutegravir (50 mg)+lamivudine (300 mg) in virologically suppressed HIV-1 patients on first-line triple-drug regimens. The main criteria for inclusion in the trial were plasma viral load (pVL) ≤50 copies/mL for ≥2 years, CD4 nadir >200 cells/mm3 and WT HIV prior to treatment initiation. From week -8 (W-8) to day 0 (D0) (Phase 1), the current third agent was switched to dolutegravir. From D0 to W48 (Phase 2), patients received once-daily dolutegravir+lamivudine, except if intolerant or if pVL >50 copies/mL during Phase 1. Virological failure was defined as pVL >50 copies/mL in two consecutive samples. The study was designed to show that the strategy had an efficacy of ≥80%, assuming a 90% success rate with a type I error of 5% and a power of 90%. RESULTS: In total, 104 of 110 patients enrolled in Phase 1 were included in Phase 2. These 104 patients were 86% male, 72% MSM and 87% CDC stage A. Their characteristics were (median): age 45 years, CD4 nadir 339 cells/mm3, baseline CD4 743 cells/mm3 and duration of viral suppression 4.5 years. The overall success rate at W48 was 97% (95% CI: 94%-100%), meeting the design expectation/assumption. Three therapeutic failures occurred: one virological failure at W4, one lost to follow-up at W32 and one interruption of therapeutic strategy at W40 after a blip (pVL 59 copies/mL but control pVL <50 copies/mL). Three viral blips occurred in two additional patients. Neither M184V nor integrase resistance mutations were detected after failure or blips. CONCLUSIONS: Dolutegravir+lamivudine is a promising maintenance therapy in HIV-1-infected patients with controlled virological suppression.
OBJECTIVES: To evaluate the dolutegravir+lamivudine combination in virologically suppressed patients living with HIV. METHODS: The ANRS 167 LAMIDOL trial was an open-label, single arm, multicentre trial assessing once-daily dolutegravir (50 mg)+lamivudine (300 mg) in virologically suppressed HIV-1patients on first-line triple-drug regimens. The main criteria for inclusion in the trial were plasma viral load (pVL) ≤50 copies/mL for ≥2 years, CD4 nadir >200 cells/mm3 and WT HIV prior to treatment initiation. From week -8 (W-8) to day 0 (D0) (Phase 1), the current third agent was switched to dolutegravir. From D0 to W48 (Phase 2), patients received once-daily dolutegravir+lamivudine, except if intolerant or if pVL >50 copies/mL during Phase 1. Virological failure was defined as pVL >50 copies/mL in two consecutive samples. The study was designed to show that the strategy had an efficacy of ≥80%, assuming a 90% success rate with a type I error of 5% and a power of 90%. RESULTS: In total, 104 of 110 patients enrolled in Phase 1 were included in Phase 2. These 104 patients were 86% male, 72% MSM and 87% CDC stage A. Their characteristics were (median): age 45 years, CD4 nadir 339 cells/mm3, baseline CD4 743 cells/mm3 and duration of viral suppression 4.5 years. The overall success rate at W48 was 97% (95% CI: 94%-100%), meeting the design expectation/assumption. Three therapeutic failures occurred: one virological failure at W4, one lost to follow-up at W32 and one interruption of therapeutic strategy at W40 after a blip (pVL 59 copies/mL but control pVL <50 copies/mL). Three viral blips occurred in two additional patients. Neither M184V nor integrase resistance mutations were detected after failure or blips. CONCLUSIONS:Dolutegravir+lamivudine is a promising maintenance therapy in HIV-1-infectedpatients with controlled virological suppression.
Authors: Mohamed N'dongo Sangaré; Jean-Guy Baril; Alexandra de Pokomandy; Steve Ferreira Guerra; Mabel Carabali; Claudie Laprise; Réjean Thomas; Marina Klein; Cécile Tremblay; Michel Roger; Costa Pexos; Zoë R Greenwald; Nima Machouf; Madeleine Durand; Isabelle Hardy; Mamadou Dakouo; Andrea Trevisan; Louise Laporte; Mireille E Schnitzer; Helen Trottier Journal: Open Forum Infect Dis Date: 2020-09-04 Impact factor: 3.835
Authors: Soo-Yon Rhee; Philip M Grant; Philip L Tzou; Geoffrey Barrow; P Richard Harrigan; John P A Ioannidis; Robert W Shafer Journal: J Antimicrob Chemother Date: 2019-11-01 Impact factor: 5.790
Authors: Erkki Lathouwers; Eric Y Wong; Kimberley Brown; Bryan Baugh; Anne Ghys; John Jezorwski; El Ghazi Mohsine; Erika Van Landuyt; Magda Opsomer; Sandra De Meyer Journal: AIDS Res Hum Retroviruses Date: 2019-10-21 Impact factor: 2.205
Authors: Darrell H S Tan; Maria Jose Rolon; Maria Ines Figueroa; Omar Sued; Ana Gun; Rupert Kaul; Janet M Raboud; Leah Szadkowski; Mark W Hull; Sharon L Walmsley; Pedro Cahn Journal: PLoS One Date: 2019-09-06 Impact factor: 3.240
Authors: Jean van Wyk; Faïza Ajana; Fiona Bisshop; Stéphane De Wit; Olayemi Osiyemi; Joaquín Portilla Sogorb; Jean-Pierre Routy; Christoph Wyen; Mounir Ait-Khaled; Maria Claudia Nascimento; Keith A Pappa; Ruolan Wang; Jonathan Wright; Allan R Tenorio; Brian Wynne; Michael Aboud; Martin J Gartland; Kimberly Y Smith Journal: Clin Infect Dis Date: 2020-11-05 Impact factor: 9.079